Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
The global Pneumococcal Vaccine market was valued at US$ 7980 million in 2020 and is expected to reach US$ 7688.7 million by the end of 2029, growing at a CAGR of 1.1% during 2021-2029.
This report focuses on Pneumococcal Vaccine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Pneumococcal Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Pneumococcal Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
1 Pneumococcal Vaccine Market Overview
1.1 Product Overview and Scope of Pneumococcal Vaccine
1.2 Pneumococcal Vaccine Segment by Type
1.2.1 Global Pneumococcal Vaccine Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 PPSV 23
1.2.3 PCV 7/13
1.2.4 PCV 10
1.3 Pneumococcal Vaccine Segment by End User
1.3.1 Global Pneumococcal Vaccine Sales Comparison by End User: (2021-2029)
1.3.2 Child
1.3.3 Adult
1.4 Global Pneumococcal Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pneumococcal Vaccine Revenue 2016-2029
1.4.2 Global Pneumococcal Vaccine Sales 2016-2029
1.4.3 Pneumococcal Vaccine Market Size by Region: 2016 Versus 2021 Versus 2029
2 Pneumococcal Vaccine Market Competition by Manufacturers
2.1 Global Pneumococcal Vaccine Sales Market Share by Manufacturers (2016-2021)
2.2 Global Pneumococcal Vaccine Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Pneumococcal Vaccine Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Pneumococcal Vaccine Manufacturing Sites, Area Served, Product Type
2.5 Pneumococcal Vaccine Market Competitive Situation and Trends
2.5.1 Pneumococcal Vaccine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Pneumococcal Vaccine Players Market Share by Revenue
2.5.3 Global Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pneumococcal Vaccine Retrospective Market Scenario by Region
3.1 Global Pneumococcal Vaccine Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Pneumococcal Vaccine Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Pneumococcal Vaccine Market Facts & Figures by Country
3.3.1 North America Pneumococcal Vaccine Sales by Country
3.3.2 North America Pneumococcal Vaccine Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Pneumococcal Vaccine Market Facts & Figures by Country
3.4.1 Europe Pneumococcal Vaccine Sales by Country
3.4.2 Europe Pneumococcal Vaccine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Pneumococcal Vaccine Market Facts & Figures by Region
3.5.1 Asia Pacific Pneumococcal Vaccine Sales by Region
3.5.2 Asia Pacific Pneumococcal Vaccine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Pneumococcal Vaccine Market Facts & Figures by Country
3.6.1 Latin America Pneumococcal Vaccine Sales by Country
3.6.2 Latin America Pneumococcal Vaccine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Pneumococcal Vaccine Market Facts & Figures by Country
3.7.1 Middle East and Africa Pneumococcal Vaccine Sales by Country
3.7.2 Middle East and Africa Pneumococcal Vaccine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Pneumococcal Vaccine Historic Market Analysis by Type
4.1 Global Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
4.2 Global Pneumococcal Vaccine Revenue Market Share by Type (2016-2021)
4.3 Global Pneumococcal Vaccine Price by Type (2016-2021)
5 Global Pneumococcal Vaccine Historic Market Analysis by End User
5.1 Global Pneumococcal Vaccine Sales Market Share by End User (2016-2021)
5.2 Global Pneumococcal Vaccine Revenue Market Share by End User (2016-2021)
5.3 Global Pneumococcal Vaccine Price by End User (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Pneumococcal Vaccine Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Pneumococcal Vaccine Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Pneumococcal Vaccine Sales, Revenue and Gross Margin (2016-2021)
6.2.4 GSK Pneumococcal Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 MSD
6.3.1 MSD Corporation Information
6.3.2 MSD Description and Business Overview
6.3.3 MSD Pneumococcal Vaccine Sales, Revenue and Gross Margin (2016-2021)
6.3.4 MSD Pneumococcal Vaccine Product Portfolio
6.3.5 MSD Recent Developments/Updates
6.4 Sanofipasteur
6.4.1 Sanofipasteur Corporation Information
6.4.2 Sanofipasteur Description and Business Overview
6.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
6.4.5 Sanofipasteur Recent Developments/Updates
6.5 CDIBP
6.5.1 CDIBP Corporation Information
6.5.2 CDIBP Description and Business Overview
6.5.3 CDIBP Pneumococcal Vaccine Sales, Revenue and Gross Margin (2016-2021)
6.5.4 CDIBP Pneumococcal Vaccine Product Portfolio
6.5.5 CDIBP Recent Developments/Updates
7 Pneumococcal Vaccine Manufacturing Cost Analysis
7.1 Pneumococcal Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Pneumococcal Vaccine
7.4 Pneumococcal Vaccine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Pneumococcal Vaccine Distributors List
8.3 Pneumococcal Vaccine Customers
9 Pneumococcal Vaccine Market Dynamics
9.1 Pneumococcal Vaccine Industry Trends
9.2 Pneumococcal Vaccine Growth Drivers
9.3 Pneumococcal Vaccine Market Challenges
9.4 Pneumococcal Vaccine Market Restraints
10 Global Market Forecast
10.1 Pneumococcal Vaccine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Pneumococcal Vaccine by Type (2022-2029)
10.1.2 Global Forecasted Revenue of Pneumococcal Vaccine by Type (2022-2029)
10.2 Pneumococcal Vaccine Market Estimates and Projections by End User
10.2.1 Global Forecasted Sales of Pneumococcal Vaccine by End User (2022-2029)
10.2.2 Global Forecasted Revenue of Pneumococcal Vaccine by End User (2022-2029)
10.3 Pneumococcal Vaccine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Pneumococcal Vaccine by Region (2022-2029)
10.3.2 Global Forecasted Revenue of Pneumococcal Vaccine by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Pneumococcal Vaccine Sales (K Doses) Growth Rate Comparison by Type (2021-2029)
Table 2. Global Pneumococcal Vaccine Sales (K Doses) Comparison by End User (2021-2029)
Table 3. Global Pneumococcal Vaccine Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers Pneumococcal Vaccine Covered in This Study
Table 5. Global Pneumococcal Vaccine Sales (K Doses) of Key Manufacturers (2016-2021)
Table 6. Global Pneumococcal Vaccine Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Pneumococcal Vaccine Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Pneumococcal Vaccine Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Pneumococcal Vaccine Average Price (USD/Dose) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Pneumococcal Vaccine Manufacturing Sites and Area Served
Table 11. Manufacturers Pneumococcal Vaccine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Pneumococcal Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pneumococcal Vaccine as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Pneumococcal Vaccine Sales by Region (2016-2021) & (K Doses)
Table 16. Global Pneumococcal Vaccine Sales Market Share by Region (2016-2021)
Table 17. Global Pneumococcal Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Pneumococcal Vaccine Sales by Country (2016-2021) & (K Doses)
Table 19. North America Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 20. North America Pneumococcal Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 22. Europe Pneumococcal Vaccine Sales by Country (2016-2021) & (K Doses)
Table 23. Europe Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 24. Europe Pneumococcal Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Pneumococcal Vaccine Sales by Region (2016-2021) & (K Doses)
Table 27. Asia Pacific Pneumococcal Vaccine Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Pneumococcal Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Pneumococcal Vaccine Revenue Market Share by Region (2016-2021)
Table 30. Latin America Pneumococcal Vaccine Sales by Country (2016-2021) & (K Doses)
Table 31. Latin America Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 32. Latin America Pneumococcal Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Pneumococcal Vaccine Sales by Country (2016-2021) & (K Doses)
Table 35. Middle East and Africa Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Pneumococcal Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 38. Global Pneumococcal Vaccine Sales (K Doses) by Type (2016-2021)
Table 39. Global Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
Table 40. Global Pneumococcal Vaccine Revenue (Million US$) by Type (2016-2021)
Table 41. Global Pneumococcal Vaccine Revenue Share by Type (2016-2021)
Table 42. Global Pneumococcal Vaccine Price (USD/Dose) by Type (2016-2021)
Table 43. Global Pneumococcal Vaccine Sales (K Doses) by End User (2016-2021)
Table 44. Global Pneumococcal Vaccine Sales Market Share by End User (2016-2021)
Table 45. Global Pneumococcal Vaccine Revenue (Million US$) by End User (2016-2021)
Table 46. Global Pneumococcal Vaccine Revenue Share by End User (2016-2021)
Table 47. Global Pneumococcal Vaccine Price (USD/Dose) by End User (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer Pneumococcal Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2016-2021)
Table 51. Pfizer Pneumococcal Vaccine Product
Table 52. Pfizer Recent Developments/Updates
Table 53. GSK Corporation Information
Table 54. GSK Description and Business Overview
Table 55. GSK Pneumococcal Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2016-2021)
Table 56. GSK Pneumococcal Vaccine Product
Table 57. GSK Recent Developments/Updates
Table 58. MSD Corporation Information
Table 59. MSD Description and Business Overview
Table 60. MSD Pneumococcal Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2016-2021)
Table 61. MSD Pneumococcal Vaccine Product
Table 62. MSD Recent Developments/Updates
Table 63. Sanofipasteur Corporation Information
Table 64. Sanofipasteur Description and Business Overview
Table 65. Sanofipasteur Pneumococcal Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2016-2021)
Table 66. Sanofipasteur Pneumococcal Vaccine Product
Table 67. Sanofipasteur Recent Developments/Updates
Table 68. CDIBP Corporation Information
Table 69. CDIBP Description and Business Overview
Table 70. CDIBP Pneumococcal Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2016-2021)
Table 71. CDIBP Pneumococcal Vaccine Product
Table 72. CDIBP Recent Developments/Updates
Table 73. Production Base and Market Concentration Rate of Raw Material
Table 74. Key Suppliers of Raw Materials
Table 75. Pneumococcal Vaccine Distributors List
Table 76. Pneumococcal Vaccine Customers List
Table 77. Pneumococcal Vaccine Market Trends
Table 78. Pneumococcal Vaccine Growth Drivers
Table 79. Pneumococcal Vaccine Market Challenges
Table 80. Pneumococcal Vaccine Market Restraints
Table 81. Global Pneumococcal Vaccine Sales Forecast by Type (2022-2029) & (K Doses)
Table 82. Global Pneumococcal Vaccine Sales Market Share Forecast by Type (2022-2029)
Table 83. Global Pneumococcal Vaccine Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 84. Global Pneumococcal Vaccine Revenue Market Share Forecast by Type (2022-2029)
Table 85. Global Pneumococcal Vaccine Sales Forecast by End User (2022-2029) & (K Doses)
Table 86. Global Pneumococcal Vaccine Sales Market Share Forecast by End User (2022-2029)
Table 87. Global Pneumococcal Vaccine Revenue Forecast by End User (2022-2029) & (US$ Million)
Table 88. Global Pneumococcal Vaccine Revenue Market Share Forecast by End User (2022-2029)
Table 89. Global Pneumococcal Vaccine Sales Forecast by Region (2022-2029) & (K Doses)
Table 90. Global Pneumococcal Vaccine Sales Market Share Forecast by Region (2022-2029)
Table 91. Global Pneumococcal Vaccine Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 92. Global Pneumococcal Vaccine Revenue Market Share Forecast by Region (2022-2029)
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Pneumococcal Vaccine
Figure 2. Global Pneumococcal Vaccine Market Share by Type in 2020 & 2029
Figure 3. PPSV 23 Product Picture
Figure 4. PCV 7/13 Product Picture
Figure 5. PCV 10 Product Picture
Figure 6. Global Pneumococcal Vaccine Market Share by End User in 2020 & 2029
Figure 7. Child
Figure 8. Adult
Figure 9. Global Pneumococcal Vaccine Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 10. Global Pneumococcal Vaccine Market Size 2016-2029 (US$ Million)
Figure 11. Global Pneumococcal Vaccine Sales 2016-2029 (K Doses)
Figure 12. Global Pneumococcal Vaccine Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 13. Pneumococcal Vaccine Sales Share by Manufacturers in 2020
Figure 14. Global Pneumococcal Vaccine Revenue Share by Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Pneumococcal Vaccine Players: Market Share by Revenue in 2020
Figure 16. Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 17. Global Pneumococcal Vaccine Sales Market Share by Region (2016-2021)
Figure 18. Global Pneumococcal Vaccine Sales Market Share by Region in 2020
Figure 19. Global Pneumococcal Vaccine Revenue Market Share by Region (2016-2021)
Figure 20. Global Pneumococcal Vaccine Revenue Market Share by Region in 2020
Figure 21. U.S. Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Canada Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Germany Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. France Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. U.K. Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Italy Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Russia Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. China Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Japan Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. South Korea Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. India Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Australia Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Taiwan Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Indonesia Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Thailand Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Malaysia Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Philippines Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Vietnam Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. U.A.E Pneumococcal Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Pneumococcal Vaccine by Type (2016-2021)
Figure 46. Sales Market Share of Pneumococcal Vaccine by End User (2016-2021)
Figure 47. Sales Market Share of Pneumococcal Vaccine by End User in 2020
Figure 48. Revenue Share of Pneumococcal Vaccine by End User (2016-2021)
Figure 49. Revenue Share of Pneumococcal Vaccine by End User in 2020
Figure 50. Manufacturing Cost Structure of Pneumococcal Vaccine
Figure 51. Manufacturing Process Analysis of Pneumococcal Vaccine
Figure 52. Pneumococcal Vaccine Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
